TP53 and myelodysplastic syndrome: Recently, we demonstrated the importance of MDM2 in the activity of lenalidomide, whereby inhibition of the E3 ubiquitin ligase activity of MDM2 resulted in stabilization of the protein and corresponding degradation of p53 in del(5q) MDS, illustrating the critical role of these proteins in MDS disease biology, progression and therapeutic response [4].